Review
Immunology
Sihang Yu, Lei Zhou, Jiaying Fu, Long Xu, Buhan Liu, Yuanxin Zhao, Jian Wang, Xiaoyu Yan, Jing Su
Summary: There is increasing evidence showing the crucial role of the immune microenvironment, particularly the polarization state and function of macrophages, in the development of hepatocellular carcinoma. Tumor-derived exosomes in hepatocellular carcinoma act as information carriers and regulate the physiological state of cells in the microenvironment, thus controlling cancer progression. This review focuses on the role of exosome content in disease outcomes at different stages of hepatitis B virus/hepatitis C virus-induced hepatocellular carcinoma, and explores the mechanism by which macrophages contribute to hepatocellular carcinoma formation and the regulation of macrophage functions by the heterogeneity of exosome loading. The application prospects of exosome-based targeted drug delivery in immunotherapy research on hepatocellular carcinoma are also summarized.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Junru Chen, Chaofeng Ding, Yunhao Chen, Wendi Hu, Chengkuan Yu, Chuanhui Peng, Xiaode Feng, Qiyang Cheng, Wenxuan Wu, Yuejie Lu, Haiyang Xie, Lin Zhou, Jian Wu, Shusen Zheng
Summary: Lipid metabolic reprogramming is crucial for hepatocellular carcinoma (HCC) development, with long chain acyl CoA synthetase 4 (ACSL4) playing a key role in modulating de novo lipogenesis and promoting HCC progression. Mechanistically, ACSL4 upregulates SREBP1 to regulate lipogenesis in HCC cells, with a positive correlation between ACSL4 and SREBP1 expression in HCC patients, suggesting a potential combinational biomarker for predicting HCC.
Article
Pharmacology & Pharmacy
Huannan Meng, Mengqin Shen, Jiajin Li, Ruixue Zhang, Xi Li, Li Zhao, Gang Huang, Jianjun Liu
Summary: In this study, it was demonstrated that CBF effectively inhibited HCC by promoting cell apoptosis, inducing cell cycle arrest, and suppressing lipogenesis. The results showed a significant reduction in tumor growth rate and changes in fatty acid profiles after CBF treatment. Mechanistically, CBF selectively targeted SREBP1 to hinder lipid synthesis, suggesting its potential as a therapeutic agent for HCC.
EUROPEAN JOURNAL OF PHARMACOLOGY
(2021)
Article
Medicine, General & Internal
Chin-Ho Tsao, Rong-Hong Jhou, Chien-Chih Ke, Chun-Wei Chang, Chi-Wei Chang, Bang-Hung Yang, Wen-Sheng Huang, Bing-Fu Shih, Ren-Shyan Liu
Summary: Proposed a imaging probe that can assess the lipogenic activity of hepatocellular carcinoma (HCC) and predict the response to lipogenesis-targeted therapy.
FRONTIERS IN MEDICINE
(2022)
Review
Oncology
Shuqi Xie, Mengchao Wang, Chuanxiu Zeng, Yan Ou, Lu Zhao, Dong Wang, Liwei Chen, Fanming Kong, Dan Yi
Summary: This paper reviews the research progress of molecular-targeted drugs combined with immune checkpoint inhibitors in the treatment of hepatocellular carcinoma, discussing the effectiveness and safety of the combination to provide references for further application in clinical practice.
FRONTIERS IN ONCOLOGY
(2023)
Review
Pharmacology & Pharmacy
Hang Sun, Huayu Yang, Yilei Mao
Summary: Hepatocellular carcinoma (HCC) is a highly prevalent and fatal cancer, with limited treatment options due to late-stage diagnosis and drug resistance. Targeted therapies, such as Sorafenib and tyrosine kinase inhibitors, have shown some benefits in HCC patients. However, the disease's heterogeneity and resistance remain significant challenges. The development of patient-derived preclinical models and personalized treatment strategies offer opportunities for improved outcomes.
FRONTIERS IN PHARMACOLOGY
(2023)
Article
Chemistry, Multidisciplinary
An-Tian Huang, Jun Du, Zhi-Yong Liu, Guang-Cong Zhang, Weinire Abuduwaili, Jia-Yan Yan, Jia-Lei Sun, Ru-Chen Xu, Tao-Tao Liu, Xi-Zhong Shen, Ling Dong, Ji-Min Zhu, Yuhao Li
Summary: This study developed a novel nanoparticle based on photothermal therapy, which can enhance the therapeutic effect and reduce the adverse effects of hepatocellular carcinoma.
Review
Pharmacology & Pharmacy
Anita Bakrania, Gang Zheng, Mamatha Bhat
Summary: This review highlights the progress, challenges, and targeting opportunities in HCC nanomedicine based on the growing literature in recent years. However, the translation of nanotheranostics in HCC is complicated by factors such as molecular heterogeneity and concomitant liver dysfunction.
Review
Oncology
Carmelo Laface, Palma Fedele, Felicia Maria Maselli, Francesca Ambrogio, Caterina Foti, Pasquale Molinari, Michele Ammendola, Marco Lioce, Girolamo Ranieri
Summary: Hepatocellular carcinoma is the most common primary liver cancer with poor prognosis. New molecular targeted therapies have shown promising results in recent years. However, research into new treatments is still necessary.
Article
Pharmacology & Pharmacy
Lei Ding, Ping Zhang, Xu Huang, Kunmeng Yang, Xingkai Liu, Zhenxiang Yu
Summary: A responsive nanogel that can respond to intracellular reduction microenvironments has been developed for the treatment of hepatocellular carcinoma (HCC), showing excellent antitumor efficacy and minimal side effects.
FRONTIERS IN PHARMACOLOGY
(2022)
Review
Oncology
Mengke Niu, Ming Yi, Ning Li, Kongju Wu, Kongming Wu
Summary: Hepatocellular carcinoma (HCC) is a significant global health issue, and targeted therapy has made a breakthrough in treating advanced HCC. The combination of targeted therapy with immune checkpoint inhibitors shows more potent anticancer effects.
FRONTIERS IN ONCOLOGY
(2021)
Article
Biochemistry & Molecular Biology
Meghan M. Bell, Nicholas T. Gutsche, A. Paden King, Kwamena E. Baidoo, Olivia J. Kelada, Peter L. Choyke, Freddy E. Escorcia
Summary: GPC3 is expressed in HCC, making it a promising therapeutic target, but GC33 alone has not shown therapeutic efficacy. Functionalizing the antibody with therapeutic radionuclides, such as Ac-225, may be a viable approach.
Article
Chemistry, Multidisciplinary
Sibei Lei, Xiaohua Chen, Yan Gao, Ming Shuai, Weilin Zhou, Jingmei Li, Jieping Wu, Ke Men, Xingmei Duan
Summary: mRNA-based gene therapy shows promise for treating hepatocellular carcinoma (HCC), but lacks precision in vivo. This study develops a novel HCC-specific peptide, HCC167, which can specifically recognize HCC cells and facilitate active targeting. When loaded with Bims-encoding mRNA, the HCC167-modified nanoparticles effectively suppress HCC progression in multiple models. The study also identifies the ALPPL2 protein as the specific binding receptor of the HCC167 peptide. This research demonstrates a potent active targeting strategy for mRNA-based HCC therapy.
ADVANCED FUNCTIONAL MATERIALS
(2022)
Review
Oncology
Carmelo Laface, Girolamo Ranieri, Felicia Maria Maselli, Francesca Ambrogio, Caterina Foti, Michele Ammendola, Marigia Laterza, Gerardo Cazzato, Riccardo Memeo, Giovanni Mastrandrea, Marco Lioce, Palma Fedele
Summary: One of the most important abilities of a tumor is to establish immunosuppression inside the tumor microenvironment. This is achieved through various mechanisms of tumor immune escape identified in experimental studies. In the liver, the microenvironment is oriented towards immune tolerance, preventing autoimmune reactions. Additionally, hepatocellular carcinoma often develops in the context of chronic inflammation. Due to these factors, different immunotherapeutic strategies have been developed and evaluated for advanced HCC. This review provides an overview of the clinical applications of immunotherapy for advanced HCC, including approved drugs and ongoing clinical trials.
Review
Biochemistry & Molecular Biology
Christos Damaskos, Nikolaos Garmpis, Dimitrios Dimitroulis, Anna Garmpi, Iason Psilopatis, Panagiotis Sarantis, Evangelos Koustas, Prodromos Kanavidis, Dionysios Prevezanos, Gregory Kouraklis, Michail Karamouzis, Georgios Marinos, Konstantinos Kontzoglou, Efstathios A. Antoniou
Summary: This review article discusses the characteristics of hepatocellular carcinoma (HCC) and presents the progress in HCC therapy through targeted therapies. The development of efficient molecular markers and alternative therapeutic targets are emphasized.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)